STOCK TITAN

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA), a clinical-stage biopharmaceutical company focused on developing medicines targeting intracellular areas, announced its CEO, Dipal Doshi, will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event will occur on May 20, 2024, at NASDAQ in New York, NY, starting at 9:30 a.m. Eastern Time. A live webcast and a 90-day replay will be accessible on the company's website.

Positive
  • CEO participation in a high-profile investor conference may increase company visibility.
  • Live webcast access can engage a broader audience, including potential investors.
  • A 90-day replay availability ensures extended information dissemination and investor engagement.
Negative
  • No new clinical or financial data revealed in the announcement, limiting immediate investor insights.
  • The announcement lacks detailed updates on drug development progress or upcoming milestones.

BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ in New York, NY. The fireside chat will be held on Monday, May 20, 2024, at 9:30 a.m. Eastern Time.

A live webcast will be available on the Investor Relations section of the Company’s website at www.entradatx.com. A replay will be available on the Entrada website for 90 days following the event.

About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of active moieties into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. The Company’s lead oligonucleotide programs are in development for the treatment of people living with Duchenne muscular dystrophy who are exon 44, 45 and 50 skipping amenable. Entrada has partnered VX-670, a clinical-stage program for the treatment of myotonic dystrophy type 1.

For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.

Investor and Media Contact
Karla MacDonald
Chief Corporate Affairs Officer
kmacdonald@entradatx.com


FAQ

What is the event where Entrada Therapeutics' CEO will present?

Entrada Therapeutics' CEO will present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference.

When is the H.C. Wainwright 2nd Annual BioConnect Investor Conference?

The conference is scheduled for May 20, 2024.

Where can I watch the live webcast of Entrada Therapeutics' presentation?

The live webcast will be available on the Investor Relations section of Entrada's website.

How long will the replay of the Entrada Therapeutics presentation be available?

The replay will be available for 90 days following the event.

What is the stock symbol for Entrada Therapeutics?

The stock symbol for Entrada Therapeutics is TRDA.

Entrada Therapeutics, Inc.

NASDAQ:TRDA

TRDA Rankings

TRDA Latest News

TRDA Stock Data

623.84M
37.20M
12.99%
80.07%
5.56%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOSTON